

### **CENTRAL PUBLIC SECTOR ENTERPRISES (CPSEs)**

There are five Central Public Sector Enterprises (CPSEs) under the administrative control of the Department of Pharmaceuticals. Of the five PSUs, three viz. Indian Drug & Pharmaceuticals Limited (IDPL), Hindustan Antibiotic Limited (HAL) & Bengal Chemicals & Pharmaceuticals Limited (BCPL) are sick and referred to Board for Industrial & Financial Reconstruction (BIFR). Rajasthan Drugs & Pharmaceuticals Limited (RDPL) has reported losses since 2013-14 and is incipient sick. Karnataka Antibiotic & Pharmaceuticals Limited (KAPL) is the only profit making CPSE.

(As on March 2020)

	<b>HAL</b>	<b>IDPL</b>	<b>RDPL</b>	<b>BCPL</b>	<b>KAPL</b>
<b>Established in</b>	1954	1961	1978	1981	1981
<b>Classification</b>	Sick	Sick	Incipient sick	Sick (now Profit Making)	Profit Making
<b>Net worth ( in cr.)</b>	-568.99	-7785.65	* Accounts been finalized.	-53.71	198.87
<b>Turnover ( in cr.)</b>	61.25	12.78	Nil	70.28	437.08
<b>Operating profit/loss( in cr.)</b>	-45.55	-14.00	Balance sheet not finalized	20	31.51
<b>Liabilities ( in cr.)</b>	1071.11	7860.65	78.53	208.92	168.81
<b>Referred to BIFR</b>	1997	1992	No	1992	NA
<b>Total land</b>	263.57 acres	2004 acre	9.35 acre	72.89 acre	40.34 acres
<b>Leasehold</b>	Nil	1022 acre	9.35 acre	1.10 acre	Nil
<b>Freehold</b>	263.57 acres	982 acre	Nil	71.79 acre	40.34 acres

#### **Cabinet decisions on Pharma PSUs**

1. The Cabinet in its meeting held on 28.12.2016 decided that:  
Only that much of surplus land of HAL, IDPL, RDPL and BCPL as would be required to meet the liabilities be sold through open competitive bidding to Government agencies and the outstanding liabilities be cleared from the sale proceeds. Voluntary Separation Scheme/ Voluntary Retirement Scheme also be implemented in these PSUs to pave way for their closure. Remaining part of the land should be managed in accordance with guidelines of Department of Investment and Public Asset Management

(DIPAM) and Department of Public Enterprises (DPE) in this regard and if need be, vested in a SPV created for this purpose.

- After liabilities have been met, balance sheet cleansed and the Voluntary Separation Scheme/Voluntary Retirement Scheme effected, the Department to close IDPL and RDPL and HAL and BCPL be put up for strategic sale.
  - While taking a decision to close the PSUs, the Department may also explore the possibility of hiving off the subsidiary companies of HAL and IDPL for private participation, wherever found viable.
2. Cabinet Committee on Economic Affairs (CCEA) in its meeting held on 1.11.2017 has 'in principle' approved strategic disinvestment of 100% Government of India equity in Karnataka Antibiotics & Pharmaceuticals Limited (Karnataka Antibiotics & Pharmaceuticals Ltd.) Bengaluru through a two-stage auction process, wherein the first stage would lead to a shortlist of eligible bidders, and the second stage be competitive financial bidding. The valuation of the firm would be done using a combination of Discounted Cash Flow method, relative valuation and asset-based valuation of the firm's land.

## **1. INDIAN DRUGS AND PHARMACEUTICALS LTD. (IDPL)**

### **Background:**

Indian Drugs & Pharmaceuticals Limited (IDPL) was incorporated as a public limited company on 5th April, 1961 under the Companies Act, 1956. The main objectives of the company were to create self-sufficiency in respect of essential life saving medicines, to free the country from dependence on imports and to provide medicines to the millions at affordable prices. IDPL was basically conceived and established as a part of Healthcare Infrastructure and has played a pioneering infrastructural role in the growth of Indian Drugs Industry base.

The Registered Office of the Company is located at IDPL Complex, Dundahera, Gurugram, Haryana. The company has three main Plants at Rishikesh (Uttarakhand), Gurugram (Haryana), Hyderabad (Telangana) and two 100% wholly owned subsidiaries, namely, IDPL (Tamil Nadu) Limited, Chennai (Tamil Nadu) and Bihar Drugs & Organic Chemicals Limited (BDOCL) at Muzaffarpur (Bihar). In addition, IDPL has one Joint Venture, promoted in collaboration with Industrial Promotion & Investment Corporation of Orissa Limited (IPICOL), Government of Odisha, namely Odisha Drugs & Chemicals Ltd. (ODCL) Bhubaneswar having share of 51% and 49% respectively.

IDPL played a major role in the strategic National Health Programmes like Family Welfare Programme & Populations Control (Mala-D & Mala-N), anti-malarial (Chloroquine) and prevention of dehydration (ORS) by providing quality medicines. IDPL has encouraged indigenous production and supporting Government in meeting emergent situations in Cyclone, Flood and Earthquake in Odisha, Uttarakhand and J&K providing life saving medicines on time. IDPL has always supplied quality medicines and its presence has played a price balancing role in the competitive and pharmaceutical business environment.

### **Past Achievements:**

The main objectives of setting-up IDPL were not to earn profits but to encourage indigenous production of pharmaceuticals and to support various health programmes of the Central Government. IDPL did reasonably well on this account despite the fact that it was the first integrated and monolithic venture in the public sector engaged in production of low margin products. IDPL earned Profit before Depreciation, Interest & Tax (PBDIT) from 1965 to 1968 and again from 1971 to 1974. The Company earned net profit from five years continuously from 1974 to 1979 but lost its profitability primarily due to change in Government policy about import of bulk drugs from supply to pharmaceuticals Industry. The Imports, which were earlier canalized through IDPL till 1979, were entrusted to State Trading Corporation (STC), thus divesting it of a profit making segment.

### **Reasons for sickness:**

The net worth of the IDPL became negative in 1982-83, mainly on account of:

- large monolith-type integrated production facilities producing chemicals, Bulk Drugs and Formulations;
- Out-dated Plant & Machinery and obsolete technology for Bulk Drugs
- Excess manpower, high wages/salary bill and maintenance of huge township, schools and hospitals in all locations of IDPL.
- Medicines manufactured by IDPL were under Drugs Price Control Order (DPCO) by the Government prior to liberalization in 1991.
- Shift in Government policy resulting in shifting of the canalization agency from IDPL to State Trading Corporation (STC).
- Intense competition from private pharmaceuticals companies which did not have to bear the burden of social infrastructure of setting up and maintaining townships, schools, hospitals etc. and had leaner production facilities.

**Revival plans:**

The erstwhile Board for Industrial & Financial Reconstruction (BIFR) declared IDPL as a sick industrial Company in August, 1992. In February, 1994, BIFR approved the Rehabilitation Scheme under Section 17(2) of SICA. The package, however, failed primarily because:

- Full funds were not released to the company as envisaged
- capital restructuring was not done
- Banks did not provide adequate working capital requirements
- Working capitals were diverted to meet fixed expenses of subsidiary units.
- Land could not be sold
- Sales targets were fixed at very ambitious levels.

In January, 1996, BIFR appointed Industrial Development Bank of India (IDBI) as Operating Agency (OA) for Techno-Economic Analysis and preparation of Revival Package. The issue of revival of the company remained pending in BIFR as well as with the Govt. while attempts were made in 2001-02 to privatize the Company. OA (IDBI) however, did not find any proposal worthy of recommendations to BIFR.

After failure to privatize, BIFR ordered winding “up of the company in December, 2003. Govt. filed an appeal before Appellate Authority for Industrial Financial Reconstruction (AAIFR) against BIFR order. AAIFR, while admitting the appeal filed by the Government directed that a Road Map for revival of IDPL be submitted. An Expert Committee, constituted by the Department found the Plant & Machineries for production of formulations in a reasonably good shape which could be optimally utilized with minimal investment for compliance of Scheme-M requirements. It was also opined that the emerging position of IDPL in the present market scenario was to be conceptualized. IDBI supported the recommendations of the Expert Committee. Having regard to these developments, AAIFR in its hearing held in September, 2005 set aside the winding up order and remanded the matter back to BIFR for taking further action for Rehabilitation of IDPL and to pass further orders in accordance with Law.

Accordingly, a Draft Rehabilitation Scheme (DRS) was prepared by IDPL and submitted to the BRPSE for consideration and recommendation. After approval of the BRPSE, a Note for Cabinet Committee on Economic Affairs (CCEA) was prepared and submitted for approval on 11.5.2007. The Note was considered by CCEA in its meeting held on 17.5.2007 and it referred the matter to Group of Ministers (GoM). The GoM in its meeting held on 11.10.2007 advised that IDPL’s revival plan should be based on public interest goals and ensuring viability of the Company. In view of the observations made by GoM,

IDPL appointed a leading consultant Company E&Y to carry out the feasibility study. E&Y report was submitted to the Ministry/DoP.

A revised DRS again prepared in consultation with IDBI (OA), on the basis of report prepared by E&Y, taking cut-off date as 31st March, 2011. In the BIFR meeting held on 20.8.2014 cut-off date was approved as 31.3.2014. Accordingly, the revised updated DRS was prepared and submitted to the Department in January, 2015. However, the Cabinet in its meeting held on 28.12.2016 recommended for closure of the company after meeting its liabilities from the proceeds of sale of surplus land through open competitive bidding to Government Agencies. The follow-up action for implementation of the decision is under way.

### **100% IDPL WHOLLY OWNED SUBSIDIARIES**

#### **a) IDPL (Tamil Nadu) Ltd, Chennai.**

IDPL (TN) Ltd. Chennai was incorporated in September, 1965, initially it was a Surgical Instruments Plant and later diverted for formulations. In terms of revival package approved by BIFR in 1994 this Plant was converted into a wholly owned subsidiary in the name and style of IDPL (Tamilnadu) Limited, Chennai with effect from 1.4.1994.

IDPL (Tamilnadu) is a Schedule-M compliant plant and was engaged in manufacture of pharmaceuticals formulations prior to its closure in July 2018.

#### **b) Bihar Drugs & Organic Chemicals Ltd. (BDOCL), Muzaffarpur**

Bihar Drugs & Organic Chemicals Ltd., (BDOCL) Muzaffarpur was incorporated in 1979, converted into a wholly owned subsidiary with effect from 1.4.1994. IDPL holds the entire equity capital of this Unit. Since November 1996 there is no production activity in BDOCL Plant .

### **JOINT VENTURE**

#### **Orissa Drugs and Chemicals Ltd (ODCL)**

Orissa Drugs & Chemicals Limited (ODCL) was incorporated in 1979 and commissioned fully for production from September, 1983. ODCL is a Joint Venture promoted by Indian Drugs & Pharmaceuticals Ltd. (IDPL) and Industrial Promotion & Investment Corporation of Orissa (IPICOL). IDPL holds 51% of the equity shares and 49% is with IPICOL. BIFR passed orders for winding up in April, 2003 under the provisions of SICA Act, 1985. High Court of Orissa had appointed a provisional Liquidator. This has since been stayed by a larger Bench of the Odisha High Court.

Presently Company is engaged in manufacture of pharmaceuticals formulations in the form of Tablets, Capsules, Powder, ORS and Injectables etc. ODCL Plant is Schedule-M compliant and company has earned operating profit since 2011-12 .

### **IDPL, IDPL(TN), BDOCL & ODCL today**

All IDPL plants at Gurugram, Rishikesh and Hyderabad and subsidiaries viz. IDPL(TN) at Chennai and BDOCL, Muzaffarpur(Bihar) are under closure as per decision of the Union Cabinet in its meeting held on 28.12.2016 and conveyed vide Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals vide its letter No 54014/1/2016-PSU dated 09.01.2017.

**Production:** All IDPL plants at Gurugram, Rishikesh and Hyderabad, IDPL (TN) at Chennai and BDOCL, Muzaffarpur (Bihar) have ceased production activities in terms of Cabinet decision to close down IDPL and subsidiaries.

### **Production and Sales up to FY 2019-2020 (value in Cr.)**

Subject	2011-12	2012-13	2013-14	2014-15	2015-16	2016-17	2017-18	2018-19	2019-20
Production	50.71	58.71	62.83	71.31	87.96	78.34	33.15	33.66	7.91
Sales	50.69	59.47	60.18	63.50	86.41	79.45	84.22	33.96	12.78

**Manpower:** Presently IDPL has no regular employees as all regular employees of IDPL have been retired under Voluntary Retirement Scheme (Gujarat Pattern) on 30.06.2020. Currently IDPL has 82 employees (as on 19.10.2020) on fix term contractual basis in different locations of the Company including 100% wholly owned Subsidiaries. The Company appointed contractual manpower only in statutory and critical positions. Third party outsourced manpower is employed on security and worker category duties.

**Marketing:** The Company earlier used to supply its products to Govt. Institutions on PPP as per NPPA certified rates. Major Institutional customers were ESIC, Ministry of Health, Defence, Railways, State Governments/Corporations and Public Sector Hospitals which used to place orders under different therapeutic categories of medicines. Apart from above the Company actively supported the Pradh Mantri Bhartiya Janaushadhi Pariyojana (**PMBJP**).

### **Actions taken in compliance with Union Cabinet decision to close down IDPL and Subsidiaries:**

**Valuation of movable & immovable assets and their disposal:** In terms of DPE guidelines for closure of CPSEs and disposal of assets vide DPE/5(1)/2014-Fin (Pt I) dated 14/06/2018, NBCC India has been appointed as Land Management agency (LMA) through an MOU for valuation of freehold land holding of IDPL at Gurugram, Rishikesh and Hyderabad and an Independent Valuation Agency appointed for valuation of plant, machinery and constructed buildings of all IDPL plants and Subsidiaries. A second Valuation agency has also been appointed for valuation of other immovable assets of IDPL. The valuation of IDPL assets in Rishikesh plant and 100% subsidiary viz. BDOCL, Muzaffarpur has been

completed and discussions with State Government have been initiated to acquire IDPL assets as a package in-lieu of part-payment of outstanding liabilities payable by IDPL to the State Government. The valuation of IDPL Gurugram and Hyderabad plant freehold land holding is complete while valuation of their plant and machinery is in progress.

The valuation of plant and machinery of IDPL(TN), Chennai plant is completed, however a response to unilateral decision of Tamilnadu State Government to cancel allotment of land and acquire the same since IDPL(TN) is non-operational is being contemplated. As mandated by DPE in its guidelines vide DPE/5(1)/2014-Fin (Pt I) dated 14/06/2018 with regard to disposal of movable and immovable assets, where no bid/response is received by the Land Management Agency in response to a RFQ advertisement from any Central Government/ State Government or their entities for freehold land holding of the CPSE or its Subsidiaries, the assets can be disposed off in a transparent manner by a Government Auctioning agency. In this regard, IDPL has already signed an MOU with MSTC India limited. The go-ahead from controlling Ministry and Group of Ministers constituted for the purpose is awaited.

At present IDPL's JV Company, ODCL, Bhubaneshwar continues to be engaged in manufacture of pharmaceuticals formulations on a limited scale.

## 2. HINDUSTAN ANTIBIOTICS LIMITED (HAL)

### Brief:

Hindustan Antibiotics Ltd (HAL) is wholly owned Government Company engaged in the manufacturing & marketing of life saving drugs. HAL was established in 1954 with WHO/ UNICF assistance. HAL is first to Manufacture the Antibiotics like Bulk drugs, Streptomycin and Gentamycin. HAL has rare distinction of inventing two new molecules viz. Hamycin and Auerofungin. HAL, at present, is bouncing back to productive and efficient work culture and taking all the steps to achieve the enhanced turnover and profitability for the company.

### Subsidiaries of HAL:

Sr. No.	Particulars	Year
1	Subsidiaries	
a.	Maharashtra Antibiotics and Pharmaceuticals Limited (MAPL)	1979 till date
b.	Manipur State Drugs & Pharmaceuticals Limited (MSDPL)	1989 till date

AL  
manuf  
acturi  
ng  
faciliti

es include the following:-

- a) Bulk Plant:  
HAL is having fermentation based manufacturing facilities including 19X92M3 fermentor along with its downstream processing, solvent recovery and associated utilities like steam, chilled water, cooling tower water, compressed air etc. This facilities earlier was used for manufacturing fermentation based bulks like Penicillin-G, Streptomycin Sulphate. This facilities is idle at present.
- b) Formulation facility:  
HAL is focusing at present on manufacturing Pharma formulation and promising Agro-formulation to cater to wide range of Pharma and Agro market. HAL Pharma products includes various dosage forms like Injectable products, Tablets, Capsules, Intra-Venous products, Liquid Syrup etc. At present, manufacturing formulation capacities including Pharma & Agro-Chem, are as follows:-

Sr.No.	Production facilities	Capacities (Existing) Lac Nos. / annum



<b>A.</b>	<b>Pharma Plants</b>	
<b>1</b>	<b>Powder Injectable</b>	
a.	Cephalosporin	450
b.	Penicillin	450
<b>2</b>	<b>Tablets</b>	
a.	Penicillin	1200
b.	Non-Penicillin	2400
<b>3</b>	<b>Penicillin Capsules</b>	<b>2500</b>
<b>4</b>	<b>I.V.Fluids</b>	<b>120</b>
<b>5</b>	<b>Liquid Syrup &amp; External preparation</b>	<b>24</b>
<b>B</b>	<b>Agro-Chem Plants</b>	
1	Agro- Chem (Streptocycline)	180
2	Humaur formulation	210 KL*
3	Aureofungin Bulk	0.810 tonnes
4	Azetomeal	50 KL*
5	Phosphmeal	50 KL*
<b>C</b>	<b>Alcoholic Hand Disinfectant (AHD)</b>	12

\*Capacity of these products can be increased depending upon requirement since HAL is having idle sizable fermentation facilities

- c) HAL has entered into MoU with another CPSU M/s Mishra Dhatu Nigam Ltd. (MIDHANI), under the administrative control of Ministry of Defence, for marketing of Bio-Implants manufactured by MIDHANI.
- d) HAL has re-started manufacturing of following Agro Products which were closed down for the last 8 to 10 years:
- i) Aureofungin
  - ii) Humaur
  - iii) Phosphomeal
  - iv) Azetomeal

e) During the year 2019-20, HAL has re-started marketing of one of its premium product which was closed down since 2010, namely Pen-V tablet, which is used in curing Rheumatic Heart Disease. HAL is proud to state that it is the only unit in the country, for manufacturing of Pen-V tablets.

**f) Research and Development :**

HAL's R & D Department is engaged in manufacturing standard size Narcotic Drugs Detection Kits, Precursor Chemicals Detection Kits and Ketamine Detection Kits as per requirements of Narcotic Control Bureau, Department of Internal Security, Ministry of Home Affairs, Govt. of India, New Delhi. HAL is the only exclusive manufacturer of this product in the country.

## **Present Status of the Company**

Subsequent to Cabinet decision of strategic sale of the company, the company has given VRS to 372 employees. HAL is having 263 acres of land, out of which 87.70 acres of land has been identified as surplus. The Company has signed an MOU with NBCC on 26.10.2019 as Land Management Agency for sale of land. The Company has submitted details of surplus land of HAL and all properties of its 2 Subsidiary Companies namely, MAPL, Nagpur and MSDPL, Manipur to NBCC. The valuation report of the land has been submitted by M/s NBCC.

### **6. Details of Production, Sales Turnover and Net Profit / Loss for the last three years are as below :**

**(Rs in Crores)**

	<b>2015-16</b>	<b>2016-17</b>	<b>2017-18</b>	<b>2018-19</b>	<b>2019-20</b>
Production	14.45	11.36	37.44	54.51	43.05
Sales Turnover	15.12	10.73	35.21	66.85	61.25
Net Profit (Loss)	(74.68)	78.24	208.32*	(71.10)	(138.30)#

\*The said Net Profit is the result of an extraordinary item of income viz. waiver by Govt. of India of its Plan and Non-Plan loan of Rs.186.96 crores and the interest there on of Rs.89.94 crores. Total Rs.276.90 crores.

# The net operating loss for the year is Rs. 72.42 crores which has increased due to employee separation Costs (VRS) impact of Rs. 65.88 crores hence the total net loss is arrived Rs. 138.30 crores.

### **Projects implemented so far:**

HAL has completed setting-up of new Cephalosporin power injectable facilities. This facility was accredited with WHO-GMP certification in July 2010. The upgradation of Betalactam & Quality Control Lab is complete and ready for WHO-GMP inspection. Non-Parental facility is also being planned to be upgraded to WHO-GMP compliance, during 2020-21.

### **Planned Projects:**

HAL is planning upgradation of following facilities to generate more funds for the company:

- i. Facility for bulk Amoxicillin Trihydrate IP with initial capacity of around 50 to 60 Tonnes per month.

- ii Facility for bulk Sulbactam Sodium IP .
- iii Facility for Alcoholic Handrub Disinfectant, the only CPSU to have such facility.
- iv Marketing of Bio-medical Implants manufactured by Mishra Dhatu Nigam Ltd., a CPSU under the Ministry of Defence, GOI, having certification of ISO 9001:2015 & AS 9001:2016.
- v Rooftop Solar Panels for generation of power equivalent to 1 MW.

The funding for the above projects shall be done through internal resources.

### 3. KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED, BENGALURU(KAPL)

#### BACKGROUND:

Karnataka Antibiotics and Pharmaceuticals Limited (KAPL) is a Profit making Joint Sector Company incorporated in the year 1981 [with 59% share by Government of India and 41% share by Government of Karnataka through Karnataka State Industrial and Infrastructure Development Corporation (KSIIDC)]. The basic objective of the Company is to make available life saving drugs of good quality to Government Hospitals and other Institutions along with Private Medical Practitioners. The Company has WHO-GMP Certified manufacturing facilities for Dry Powder Injectables, Liquid Injectables, Tablets, Capsules, Dry Syrups and Suspensions. The paid-up share capital of the Company as on date is Rs. 13.49 crores.

#### PRODUCTION AND SALES PERFORMANCE:

(Rs. in Crores)

YEARS	PRODUCTION	SALES
2014-2015	281.81	247.24
2015-2016	342.01	326.92
2016-2017	405.51	386.27
2017-2018	366.82	353.83
2018-2019	388.63	360.36
2019-20	489.57	437.08

#### PAST ACHIEVEMENTS:

- Mini Ratna CPSE
- ISO 9001 (QMS) AND ISO 14001 (EMS)
- PIC/S Certification

#### POPULAR BRANDS:

#### PHARMA – TRADE

No	Products	Therapy Segments	NLEM	Monopoly	Market Value
----	----------	------------------	------	----------	--------------

1	Grenil	Anti Migraine	No	No	Rs. 794.65 lakhs
2	Oxytocin	Hormone	Yes	No	Rs. 474.71 lakhs
3	Cyfolac	Probiotics	No	No	Rs. 345.32 lakhs
4	Remcc	Cough & Cold	No	No	Rs. 176.07 lakhs
5	Verclav	Antibiotic	Yes	No	Rs. 160.71 lakhs
6	POP E	Platelet Booster	No	No	Rs. 155.39 lakhs
7	Zinfe	Haematinic	No	No	Rs. 138.86 lakhs
8	Numol	Pain Medication	No	No	Rs. 111.37 lakhs

#### **AGROVET:**

<b>No</b>	<b>Products</b>	<b>Therapy Segments</b>	<b>Monopoly</b>	<b>Market Value</b>
1	Kalvimin	Animal Feed Supplement	No	Rs. 3.0 Cr
2	K-live	Liver Tonic	No	Rs. 2.5 Cr
3	Cal K	Animal Feed Supplement	No	Rs. 2.5 Cr

#### **DISTRIBUTION NETWORK:**

##### **PHARMA**

The Company has been expanding its operations in Retail Trade Sector with a planned effort so as to cater to the needs of the Private Medical Practitioners. In this direction the Company has been periodically launching New Products in the various Therapeutic Segments. The Domestic operations spans through the country manned by a highly dedicated Professional Field Force and backed by a well knit Channel of Distribution ensuring KAPL's presence at the Metro as well as Micro Markets.

KAPL has its Branches located in almost all the State Head Quarters. The Company also has an excellent Distribution Network at almost 20 branches at Major Cities catering to the respective State area through Channel Marketing. The supplies are made effective through approved Stockists to Retailers, Nursing Homes and Dispensing doctors in the Trade Segment and directly to Institutions in Rate Contract (RC) & Non-Rate Contract (NRC) Sectors.

**MARKETING:****PHARMA:**

The Company has been mainly focusing on Prescription Market as Medical Professional as our Customers, where many of the MNCs and Private Pharma Players have a major share. The Company is also dependant on PPP Policy for Institutional Business, where our concentration is on Govt. Hospitals, State Government Hospitals, Corporates, PSU Hospitals, Defence and Insurance. It has potential to expand in Trade Segment and also to increase volumes by focusing on CPSE Hospitals and large Corporate Hospitals.

**AGROVET:**

The Company is focusing on Agro Dealers, Department of Agriculture / Horticulture for Agro Products. Products are being focused on Veterinary Practitioners, Farmers, Animal Husbandary Department of all States and Milk Unions for Veterinary Products and Feed Supplements.

**NEW PRODUCTS(PHARMA & AGROVET)**

Sl.No	Products	Therapeutic Category
<b>PHARMA</b>		
a)	Kapitra 100	Antifungal
b)	Kapitra 200	Antifungal
c)	Kaplicon	Antifungal
<b>AGROVET</b>		
d)	Vet CPM Injection	Anti Alergic
e)	Pensbiotic MD 5 gm	Antibiotic

Presently Company is manufacturing and marketing Oxytocin Injection as per the decision of Government of India.

#### 4. Bengal Chemicals & Pharmaceuticals Ltd. (BCPL)

##### **Background:**

Bengal Chemicals and Pharmaceuticals Limited (BCPL), was formed in 1901 by Acharya Prafulla Chandra Roy, a renowned Scientist and Academician. Government of India had taken over its Management in 1977, nationalised in 1980 and Registered as Bengal Chemicals & Pharmaceuticals Limited (BCPL) under the Companies Act in 1981. The company was declared sick in 1992 and was sanctioned scheme for revival in 1995 by the erstwhile Board for Industrial & Financial Reconstruction (BIFR).

##### **Business Operations:**

Headquartered in Kolkata, BCPL is engaged in the business of industrial chemicals (Alum), branded and unbranded generic pharmaceuticals, hair oil and disinfectants such as Phenol, Naphthalene balls, Bleaching powder, Toilet cleaners and Floor cleaners.

**Manufacturing Locations:** At present BCPL has four factories; at Maniktala and Panihati in West Bengal, Mumbai and Kanpur.

**Maniktala Unit:** This unit was set up in 1905 and primarily produces Pharmaceuticals formulations which include branded as well as unbranded generic products. Commercial production in Tablet, Capsule and Ointment sections is going on full-fledged.

**Panihati Unit:** Panihati unit was set up in 1920 and is located in North 24 Parganas, West Bengal. Panihati unit primarily produces Industrial Chemicals and Home Products which include Pheneol, Naphthalene Balls, and other disinfectants. Commercial production in most of the renovated production-blocks such as Ferric Alum, Pheneol, Napthalene and White Tiger have commenced.

**Mumbai Unit:** Mumbai unit was set up in 1938 and further the commercial space developed has been leased out to third parties for generation of additional sources of income.

**Kanpur Unit:** Kanpur Unit was set up in 1949, primarily produces low-value tablets.

**Past Achievements:** The Company has retained its brand position in home products even during the crisis period and well set to capitalize on these brands now.

**Sickness and Revival:** The Company was referred to erstwhile BIFR in 1992. The revival package for BCPL was approved by the Government in December 2006. The package of Rs 440.60 Cr was approved which comprised of restructuring of existing debts on the books of BCPL, capital investments, support for development of marketing infrastructure and promotional measures, grant for wage revision and implementation of VRS and funds for payment of non-Government dues. Even after restructuring the Company in 2006, it was running in losses and its operational performance had come down drastically to Rs.17 Crore Turnover in 2013-14, which was the lowest ever turnover since its inception as Government of India Company, and reported a Net Loss of Rs.36.55 Crore in 2013-14. However, from the financial year 2016-17 onwards, the company became a Turnaround Company and reported a Net Profit of



Rs.4.51 Crore and a Gross Margin of Rs.24.05 Crore. In the consecutive 2<sup>nd</sup> financial year also i.e., in 2017-18, BCPL reported a Net Profit of Rs.10.06 Crore. In the year 2018-19, BCPL again reported a Net Profit of Rs.25.26 Crore. Further, BCPL has repaid the entire Bank Loan of Rs.28 Crore to United Bank of India which was taken in 1983 by mortgaging Registered Office building and now BCPL is a debt free company (except Govt. of India Loans). BCPL has also paid Rs.25 Crore to Government of India till date, towards repayment of loans taken in the year upto 2011.

**Product profile and range:**

The products manufactured under each of these business segments are mentioned below:

**Product Profile**

Division - I	Division – II		Division - III		
Industrial Chemicals	Pharma Generics	Pharma Branded	Disinfectants	Hair Oil	Other Products
Alum Bleaching Powder	Tablets, Capsules, Injectables Ointments Liquids External-Liquids ASVS	Aqua Ptychotis Kalmegh Eutheria Benflam	Pheneol White Tiger Klin Toilet Lysol	Cantharidine Hair Oil	Naphthal-ene Balls Liquid Soap Aguru Essence

**Popular brands:** Pheneol – Lamp brand, White Tiger, Naphthalene, Cantharidine Hair Oil.

**Manpower:**

Particulars	Manpower (As on 30.11.2019)
Executives	51
Supervisors	22
Workers	102
<b>Grand Total</b>	<b>175</b>

**Distribution network if any:**

The company has a strong distribution network pan India with 6 Depots and 6 C&F Agencies. BCPL has opened 5 Retail Stores in Kolkata.

**Performance:**

Details of Production, Turnover and Financial Performance of BCPL from 2013-14 onwards are as under:

(Rs. in Crores)

Particulars	2019-20	2018-19	2017-18	2016-17	2015-16	2014-15	2013-14
Production	84.19	123.45	98.18	102.69	106.70	64.10	19.70
Income	85.63	119.67	94.80	110.25	112.76	65.53	36.63
Gross Margin(Loss)	20.26	32.83	24.23	24.05	11.24	1.65	(20.36)
Interest Expenses (Finance cost)	0.68	2.45	9.05	15.07	16.42	15.36	12.85
Depreciation	5.12	5.12	5.12	4.47	3.95	3.61	3.34
Net Profit(Loss)	13.07	25.26	10.06	4.51	(9.13)	(17.32)	(36.55)

**DPE rating:**

Year	MOU Assessment	Corporate Governance
2009-10	Poor	"Poor"
2010-11	Poor	"Poor"
2011-12	Poor	"Poor"
2012-13	Poor	"Poor"
2013-14	Poor	"Poor"
2014-15	"Good"	"Fair"
2015-16	"Excellent"	"Excellent"
2016-17	"Very Good"	"Excellent"
2017-18	"Not applicable"	"Excellent"
2018-19	"Not applicable"	"Excellent"

**Marketing: Share of Institutions and retail**

SR .NO.	DIV & PRODUCTS	MARKET PROFILE/Major clients
1.	DIV I – FERRIC ALUM	NTPC ( KAHELGAON & BARH) SAIL (DURGAPUR, IISCO, BOKARO, REFRACTORY UNIT, IISCO CHASNALA) BCCL ( BOWRA & BLOCK II) IPCL ( FARAKKA, SAGARDIGHI, DISERGARH) PHE ( MALDA, SILIGURI) OTHER PRIVATE PARTY
2.	DIV II –GENERIC TABLET,CAPSULE, OINTMENT, INJECTION, LIQUID	AFMSD, ESIC, RAILWAY, SAIL, DHS, APMSIDC, OTHER STATE GOVT ,SECL, AND OTHER PSU
	DIV II – BRAND AQUAPTYCHOTIS, EUTHERIA, KALMEGH	MAINLY OTC PRODUCT. TRADE BUSINESS
3.	DIV III – COSMETIC & HOME PRODUCTS	MAINLY TRADE BUSINESS ( 70-75%) AND (25 TO 30 %) INSTITUTION BUSINESS LIKE CSD, PHE, METRO RAILWAY, NMDC, JADAVPUR UNIVERSITY ETC .

**Future Plans:**

Cabinet has decided on 28<sup>th</sup> December 2016 for strategic disinvestment of the company after meeting all its liabilities from sale of surplus land through open competitive bidding to Government Agencies. But no bidder had submitted their offer. Further, Bengal Chemicals Sramik Karmachari Union filed a Writ Petition before the Hon'ble High Court of Calcutta on 20/06/2017 against the decision of the Union Cabinet of Strategic Sale of BCPL. Vide its order dated February 13, 2018, the High Court of Calcutta has set aside the decision of the Union Cabinet regarding strategic sale of BCPL. An appeal has been filed at the Division Bench.

## 5. RAJASTHAN DRUGS & PHARMACEUTICALS LTD. (RDPL)

Rajasthan Drugs & Pharmaceuticals Limited (RDPL) is a Central Public Sector Unit in Joint Sector with a total paid-up equity capital of Rs. 4.98 crores where Government of India (GoI) and Rajasthan State Industrial Development & Investment Corporation Limited (RIICO, Govt. of Rajasthan) hold 51% and 49% shares respectively. It was incorporated in 1978 and commercial production started in 1981. The Company has its manufacturing facilities & registered office at Road no. 12, VKI Industrial Area, Jaipur (Rajasthan). The production of the Company has stopped since October 2016 due to fire incident in the Jaipur plant.

### **PERFORMANCE:-**

(Rs. in Crores)

	2016-17	2017-18	2018-19
Net Worth	(-) 39.53	(-) 54.78	(-) 69.88
Turnover	7.66	0.40	0.14
Earnings (Before Tax)	(-) 14.88	(-) 15.25	(-) 15.10
Earnings (After Tax)	(-) 14.88	(-) 15.25	(-) 15.10
Net Profit/Loss	(-) 14.88	(-) 15.25	(-) 15.10

Union Cabinet decided on 28.12.2016 for closure of RDPL, after selling its surplus land of RDPL as would be required to meet the liabilities. M/s MSTC Ltd. was appointed as auctioning agency for e-auction of RDPL on 19.04.2017. Central Government/State Government/leading PSUs/Financial Institutions were invited to bid for the land, but no response was received. The Union Cabinet has on 17.07.2019 modified its earlier decision and permitted sale of surplus land to any entity. Further, it has sanctioned Rs.43.70 crore for meeting employees' liabilities. The Company has given VRS to 99 employees and about 25 employees are in the court.

## Details of CMD/MDs of PSUs under Department of Pharmaceuticals

### **1. INDIAN DRUGS & PHARMACEUTICALS LIMITED (IDPL)**

Shri Rajneesh Tingal,  
Chairman & Managing Director(CMD)(Additional Charge),  
Indian Drugs & Pharmaceuticals Limited (IDPL),

E-mail: manoharvasudevidpl@gmail.com, idplcmd@gmail.com, r.tingal@nic.in, cfo.idpl@gmail.com,  
dps.idpl@gmail.com, headofficeidpl@gmail.com, katarian.idpl@gmail.com

Shri D.P. Singh, Mobile – 9891833805, Shri Manohar Vasudev - 09873442525

**Regd. Office:-** IDPL Corporate Office,  
IDPL Complex,Dundahera,Gurgaon – 122016  
Phone – 0124-2456025, Fax – 0124-2340612, 4303744

#### **IDPL Manufacturing Plants:-**

- 1. Rishikesh Plant:-** IDPL, Virbhadrha, Rishikesh-249202, Uttarakhand  
Contact Person:- Shri G.S. Bedi, GM(O) & (I/C)  
Mobile:- 09412153917 Phone:- 0135-2450175 Fax:- 0135-2450176  
Email:- gsbedi11@rediffmail.com
- 2. Hyderabad Plant:-** IDPL, Balanagar, Hyderabad-500037, Andhra Pradesh  
Contact Person:- Shri G. Prabhulingum, Plant Incharge  
Mobile:- 09818386149, 09989243080 Phone:- 040-23079125 Fax:- 040-23779048  
Email:- gmhyderabad@yahoo.co.in
- 3. Gurgaon Plant:-** IDPL, Old Delhi Gurgaon Road, IDPL Complex, Dundahera, Gurgaon-122016, Haryana  
Contact Person:- Shri Sanjay Kumar, GM(I/C)  
Mobile:- 9818386149, 9868327477 Phone:- 0124-2455519 Fax:- 0124-2456021, 2340612  
Email:- s.kumar17@yahoo.com

#### **IDPL Two 100% wholly owned Subsidiary Units:-**

- 1. IDPL (Tamil Nadu) Ltd., Chennai:-** Nandambakkam, Chennai-600089, Tamil Nadu  
Contact Person:- Shri G.A. Reddy, Plant I/C  
Mobile:- 09840449569 Phone:- 044-22321803 Fax:- 044-22321744  
Email:- idplgmtn@yahoo.com
- 2. Bihar Drugs & Organic Chemicals Limited (BDOCL):-** Bela Industrial Estate, Muzaffarpur-842005, Bihar  
Contact Person:- Shri V.S. Sharma, Plant I/C  
Mobile:- 09771271803 Phone:- 0621-2273023  
Email:- Sharmavs.2012@gmail.com

#### **IDPL One Joint Venture in collaboration with IPICOL:-**

**1. Orissa Drugs & Chemicals Limited (ODCL):-** Mancheswar Industrial Estate, Bhubaneshwar-751010, Orissa  
Contact Person:- Shri T.K. Pradhan, Plant I/C  
Mobile:- 09040221387 Phone:- 0674-2580250  
Email:- tarakanta56@gmail.com

**2. HINDUSTAN ANTIBIOTICS LIMITED (HAL)**

Ms. Nirja Saraf,  
Managing Director,  
Hindustan Antibiotics Limited (HAL),  
Pimpri, Pune – 411018  
Phone-020-27425409, 020-27425405  
Fax-020-27425327  
E-mail: md@halpune.in, hal\_lod@yahoo.in, nirjagupta@yahoo.com,  
Liaison Officer – Shri Ravikant Gupta, Mobile – 9871895777, Shri Ashok Gawari- 08788088980  
Delhi Office – Fax – 24364919

**HAL Subsidiary Units:-**

1. Maharashtra Antibiotics & Pharmaceuticals Ltd. (MAPL), Nagpur
2. Manipur State Drugs & Pharmaceuticals Ltd. (MSDPL), Manipur

**3. RAJASTHAN DRUGS & PHARMACEUTICALS LIMITED (RDPL)**

Ms. Nirja Saraf,  
Managing Director(Additional Charge),  
Rajasthan Drugs & Pharmaceuticals Limited (RDPL),  
Road No. 12, V.K.I. Area, JAIPUR - 302013  
Phone-0141-4107100, Fax-0141-4107101  
E-mail: nirjagupta@yahoo.com, md@halpune.in, rdplmdickapl@gmail.com, purchase.rdpl@gov.in,  
production.rdpl@gov.in, rajesh15nov@gmail.com, marketing.rdpl@gov.in  
Liaison Officer – Shri Rajesh Srivastava- 07737592475  
Other Phones:- 0141-4107108, 4107104, 4107109, 4107105

**4. BENGAL CHEMICALS & PHARMACEUTICALS LIMITED (BCPL)**

Ms. Nirja Saraf,  
Managing Director(Additional Charge),  
Bengal Chemicals & Pharmaceuticals Limited (BCPL),  
6, Ganesh Chunder Avenue, KOLKATA – 700013  
Phone-033-22363148, 033-22259502  
Fax-033-22257697, 033-22257656  
E-mail: df@bengalchemicals.co.in, bcplmdsecretariat@gmail.com, akverma.72@gmail.com, nirjagupta@yahoo.com  
Liaison Officer – Shri A.K. Verma, Mobile – 9971308305  
Other Phones:- 033-22371525/6/7667, 033-22259502/7656

**BCPL Factories:-**

1. **Maniktala Factory:-** 164, Maniktala Main Road, Kolkata-700054  
Phone:- 033-23204153/4/7/8Fax:- 033-23204156
2. **Panihati Factory:-** B.T. Road, Panihati, 24 Paraganas (North), West Bengal-700114  
Phone:- 033-25531234/1924/2017/4541Fax:- 033-25532017
3. **Mumbai Factory:-** 504, S.V. SavarkarMarg, Mumbai-400025  
Phone:- 022-24302081, 24370428Fax:- 022-24321632
4. **Kanpur Factory:-** Factory Area, Fazalganj, Kanpur-208012

Phone:- 0512-2216292

**5. KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED (KAPL)**

Shri Sunil Kumar Kaimal,  
Managing Director,  
Karnataka Antibiotics & Pharmaceuticals Limited (KAPL),  
Nirman Bhawan, Dr.Rajkumar Road,  
First Block, Rajajinagar, BANGALORE – 560010  
Phone-080-23577680 Fax-080-23371350, 080-23375086  
E-mail: kaimalsunil@yahoo.com, md@kaplindia.com, supriya@kaplindia.com, parthokapl@gmail.com,  
delhi@kaplindia.com  
Smt Supriya Kulkarni (Company Secretary & Asstt. Manager(Admin)), Mobile – 09686601217, Sh. Partho Gosh(Liaison  
Officer)-9386364170